

Creating the next era of healthcare advancements for patients



Rick Nettles, MD
Chief Scientific Officer
Scientific Affairs
J&J Innovative Medicine

At Johnson & Johnson, we are leading where medicine is going

J&J is advancing the next era of medical innovation through our continuous R&D investments, totaling \$77.7 billion since 2016.¹

1. Figure according to Johnson & Johnson internal financial accounting. Values may have been rounded.

J&J Innovative Medicine

J&J in Pennsylvania

By the numbers

8




Campuses including
Research & Development

5022



Campus
Employees

1328



Field
Employees
(Work from Home or Sales Reps)

7200



Employees Living in the
Commonwealth of
Pennsylvania

Advancing the next era of healthcare breakthroughs

\$12B

Invested to develop treatments and cures in 2023¹

>124%

More spent-on R&D than on sales and marketing in 2023¹

70+


Novel therapies and treatment options we aim to launch or file by 2030²

1. Figure according to Johnson & Johnson internal financial accounting. Values may have been rounded.

2. Johnson & Johnson. "J&J Innovative Medicine Business Overview." Slide 6. December 2023. https://jnbusinessreview.q4ir.com/files/doc_downloads/2023/12/innovative-medicine-presentation.pdf. Accessed May 2024.


Innovate with purpose

Diverse portfolio leveraging deep expertise and ingenuity



Oncology

With unwavering determination, we're working toward a bold ambition – to eliminate cancer.



Immunology

We're helping patients with immune-mediated disease reclaim their lives by delivering transformational and accessible therapies.



Neuroscience

Our mission is to help reduce the burden, disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases.

Public-Private Collaboration Fuels the US Biopharmaceutical Ecosystem

Exchange of Scientific Knowledge

Private industry, academic, and government scientists all work to understand the function of newly discovered molecular compounds and cells, strange phenomena in the body, or little-understood disease processes. When that knowledge is shared in peer-reviewed publications, scientific meetings, patents, and licensing of intellectual property, and then expanded upon, this exchange of scientific knowledge fuels the creation of ideas for new medicines.

**PHARMA
& BIOTECH**

**MEDICINES
FOR PATIENTS**

**NIH &
ACADEMIA**

**SCIENTIFIC
KNOWLEDGE
ABOUT
PATIENTS**

Patents & Licenses

Patents allow researchers to protect and license their inventions for further development and potential commercialization, enabling the US biomedical research and development ecosystem to lead the world in biopharmaceutical progress. They also play an important role on the collaboration side, as the patents help companies identify who has the right assets and intellectual capital to bring together. The security that patents provide is fundamental to encouraging collaboration and investment, and incentivizing ongoing research and development into new medicines for patients.

Research Collaboration

Because the NIH does limited research related to drug development, without the scientific and industrial expertise of the biopharmaceutical industry the knowledge resulting from basic science research would generate many ideas for potential drugs and drug targets – but very few new medicines. Though industry, academic, and government scientists are encouraged to collaborate on research questions, the biopharmaceutical industry's ability to take the necessary risks is required to build on and advance basic science research into safe and effective treatments that can be made available to patients.

What does this mean for Americans and Pennsylvanians?



Medicines sooner

Of the 37 drugs the U.S. Food and Drug Administration (FDA) approved in 2022, 68% were first approved in the U.S.



More options

78% of drugs launched by G20 nations between 2012 and 2021 were available in the U.S. within one year of their launch, compared to just 38% in the United Kingdom and 21% in Canada.



Better access

Of the 124 new cancer medicines approved globally from 2012 to 2021, American patients have access to 94% of these treatments, compared to the average of 46% in other G20 countries.

J&J Innovative Medicine uses its unique experience, scientific know-how and technology to help patients with unmet needs. Our scientists are relentlessly searching for the next breakthrough in areas of medicine that can make the biggest difference.

**At Johnson & Johnson,
we are leading where
medicine is going.**